Evidence map›Paper›PMID 35958559›Full record

ReviewFrontiers in immunology2022

Anaplastic lymphoma kinase-special immunity and immunotherapy.

Ye Guo, Hanfei Guo, Yongfei Zhang, Jiuwei Cui

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Pan-cancer analysis ofGenes & diseases · 2026
    Article
  2. Review
  3. Long-Term Safety and Management of Adverse Events Associated With Lorlatinib inJournal of the advanced practitioner in oncology · 2025
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ye GuoCancer Center, The First Hospital of Jilin University, Changchun, China.
Hanfei GuoCancer Center, The First Hospital of Jilin University, Changchun, China.
Yongfei ZhangCancer Center, The First Hospital of Jilin University, Changchun, China.
Jiuwei CuiCancer Center, The First Hospital of Jilin University, Changchun, China.
First Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in the anaplastic lymphoma kinase (

Indexed as

Antineoplastic AgentsNeoplasmsAnaplastic Lymphoma KinaseHumansImmunotherapyProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesTumor MicroenvironmentAnaplastic Lymphoma KinaseAntineoplastic AgentsProtein Kinase InhibitorsReceptor Protein-Tyrosine Kinasesanaplastic lymphoma kinaseimmune checkpoint inhibitorsimmune evasionimmunotherapytumor microenvironment

Identifiers

PMID35958559
PMCPMC9359062
OpenAlexW4287837540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.